BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33070910)

  • 1. Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.
    Balasubramanian A; Gunjur A; Gan HK; Perchyonok Y; Cher LM
    J Clin Neurosci; 2020 Sep; 79():269-271. PubMed ID: 33070910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
    Wang H; Long-Boyle J; Winger BA; Nicolaides T; Mueller S; Prados M; Ivaturi V
    J Clin Pharmacol; 2020 Sep; 60(9):1209-1219. PubMed ID: 32476174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.
    Raabe EH; Lim KS; Kim JM; Meeker A; Mao XG; Nikkhah G; Maciaczyk J; Kahlert U; Jain D; Bar E; Cohen KJ; Eberhart CG
    Clin Cancer Res; 2011 Jun; 17(11):3590-9. PubMed ID: 21636552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature.
    Takamiya S; Hatanaka KC; Ishi Y; Seki T; Yamaguchi S
    Neuropathology; 2020 Jun; 40(3):275-279. PubMed ID: 31986557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.
    Pathak P; Kumar A; Jha P; Purkait S; Faruq M; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2017 Sep; 27(5):580-589. PubMed ID: 27608415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior.
    Bannykh SI; Mirocha J; Nuno M; Lopategui J; Kandala G
    Clin Neuropathol; 2014; 33(6):388-98. PubMed ID: 25066317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of disseminated pilocytic astrocytomas.
    Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
    Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.
    Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y
    Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma.
    Bar EE; Lin A; Tihan T; Burger PC; Eberhart CG
    J Neuropathol Exp Neurol; 2008 Sep; 67(9):878-87. PubMed ID: 18716556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant KIAA1549-BRAF fusion and IDH mutation in Pediatric spinal cord astrocytoma: a case report and literature review.
    Sun M; Wang L; Lu D; Zhao Z; Teng L; Wang W; Piao Y
    Brain Tumor Pathol; 2021 Apr; 38(2):132-137. PubMed ID: 33641074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
    Eisenhardt AE; Olbrich H; Röring M; Janzarik W; Anh TN; Cin H; Remke M; Witt H; Korshunov A; Pfister SM; Omran H; Brummer T
    Int J Cancer; 2011 Nov; 129(9):2297-303. PubMed ID: 21190184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of BRAF/MEK inhibitor on BRAF V600E-mutated pilocytic astrocytoma.
    Hamada R; Akane Y; Akiyama Y; Takada K; Yamamoto M
    Pediatr Int; 2023; 65(1):e15653. PubMed ID: 37804006
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
    Jones DT; Kocialkowski S; Liu L; Pearson DM; Ichimura K; Collins VP
    Oncogene; 2009 May; 28(20):2119-23. PubMed ID: 19363522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity.
    Sadighi Z; Slopis J
    J Child Neurol; 2013 May; 28(5):625-32. PubMed ID: 23439714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type.
    Ramaglia A; Tortora D; Mankad K; Lequin M; Severino M; D'Arco F; Löbel U; Benenati M; de Leng WWJ; De Marco P; Milanaccio C; Rossi A; Morana G
    Neuroradiology; 2020 Jan; 62(1):71-80. PubMed ID: 31667545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.